Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

UK close: FTSE 100 closes higher

Wed, 16th Dec 2009 16:43

Footsie ended with gains as better than expected UK unemployment figures lifted sentiment. The number of people claiming unemployment benefit fell for the first time since February 2008 in November amid further signs the UK economy is beginning to recover from the economic downturn.The claimant count fell by 6,300 to 1.63m during November, figures from the Office of National Statistics (ONS) show.Rentokil Initial finished on top of the pile after broker Deutsche Bank raised its target price on the pest control and parcel delivery group to 145p from 143p.Insurers Resolution, Prudential and RSA were among the best performers. Part-nationalised lender Royal Bank of Scotland ended with slight gains. It is 'less risky than it used to be,' according to Citigroup analyst Leigh Goodwin. The broker has revised its forecasts for RBS, however, and now expects underlying losses per share for full year 2009 of 12.2p, with the losses reducing to 3.7p in 2010 and then turning positive at 0.7p in 2011. Lloyds was little changed despite positive broker comment. Cazenove reckons the lender could return to profit next year.There is not a single quoted company in the housebuilding sector that Citigroup does not like now that the sector has seen a 20% correction in prices in the last three months. Underlying fundamentals have improved during that period, prompting Citi to upgrade Barratt Developments, Taylor Wimpey and Redrow to 'buy'. Broker comment has also whetted appetite for Premier Foods. UBS said that despite a number of well-known drawbacks, including the stretched balance sheet and the pension liability, the business is 'fundamentally sound'. The broker has upgraded the stock to 'buy' from 'neutral', but has trimmed its price target by a couple of pence to 41p,Overall demand at GKN has been better than predicted at its last update in October and the automotive and aerospace engineer expects to make further "significant" progress in 2010. Retailer Kesa Electricals has reported a bigger than expected first half profit and better than forecast like for like sales at its Comet chain. The group made adjusted pre-tax profit of £14.9m in the six months to 31 October, trumping analysts' predictions for about £12m. It lost £103.8m a year ago due to a £114m charge. Like for like sales at Comet rose 2%, ahead of forecasts for 0-1.5%.Pub chain Punch Taverns cautioned the challenging economic environment will affect profitability in the short term and also put pressure on one of its debt measures.Oil & gas facilities service provider Petrofac expects full year profits to be at least 25% higher than last year. The company has had a good year in the contracts front and said that with trading across most of its businesses continuing to improve, it should make profit after tax of at least $330m, barring unforeseen circumstances. Power station operator Drax expects underlying profits to beat market forecasts this year, despite lower prices for electricity, but is more cautious on pricing going forward.A US Food and Drug Administration (FDA) advisory committee has given a favourable verdict on the use of AstraZeneca's anti-cholesterol drug Crestor. Copper prices have recovered enough for Namibian mining company Weatherly International to reopen its Otjihase and Matchless underground mines. Electrical component maker Laird was the star performer in the FTSE 250. It is still suffering from tough conditions seen earlier in the year, but the shares advanced after it said that it is in a strong financial position and is well-placed to benefit from investment in product development and engineering. It said it expects that underlying profit before tax for the year will be in line with market forecasts.Residential property specialist Grainger's recent 2 for 1 rights issue received an acceptance rate of 92.66%, leaving the underwriters to find buyers for 20.3m shares in the market.FTSE 100 - RisersResolution (RSL) 82.50p +4.96%Rentokil Initial (RTO) 105.00p +4.79%Liberty International (LII) 485.00p +4.35%RSA Insurance Group (RSA) 119.70p +3.46%Kazakhmys (KAZ) 1,292.00p +2.95%Prudential (PRU) 626.50p +2.79%Amec (AMEC) 775.00p +2.65%Fresnillo (FRES) 818.00p +2.63%Barclays (BARC) 292.00p +2.62%Hammerson (HMSO) 390.50p +2.60%FTSE 100 - FallersUnited Utilities Group (UU.) 502.50p -2.24%Smith & Nephew (SN.) 622.00p -1.27%Burberry Group (BRBY) 577.50p -1.11%London Stock Exchange Group (LSE) 744.00p -1.06%Imperial Tobacco Group (IMT) 1,894.00p -0.99%Cable & Wireless (CW.) 140.30p -0.85%Diageo (DGE) 1,057.00p -0.75%Reckitt Benckiser Group (RB.) 3,260.00p -0.55%British American Tobacco (BATS) 1,940.00p -0.46%InterContinental Hotels Group (IHG) 885.00p -0.45%FTSE 250 - RisersLaird (LRD) 123.00p +12.64%Avis Europe (AVE) 26.13p +12.44%AG Barr (BAG) 949.00p +11.65%Ecofin Water & Power Opportunities (ECWO) 146.50p +7.56%Redrow (RDW) 131.00p +6.94%Premier Foods (PFD) 35.12p +6.62%St James's Place (STJ) 243.10p +6.06%Barratt Developments (BDEV) 116.00p +6.03%Euromoney Institutional Investor (ERM) 438.40p +5.89%Vectura Group (VEC) 79.75p +5.77%FTSE 250 - FallersMarston's (MARS) 89.70p -6.27%Grainger (GRI) 129.00p -5.22%Punch Taverns (PUB) 77.30p -4.74%Petropavlovsk (POG) 1,077.00p -4.69%Heritage Oil (HOIL) 423.50p -3.31%Connaught (CNT) 357.20p -2.19%Enterprise Inns (ETI) 98.65p -2.13%VT Group (VTG) 516.00p -1.99%International Personal Finance (IPF) 210.00p -1.87%PartyGaming (PRTY) 252.30p -1.87%

Related Shares

More News
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with infla...

18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with pacl...

17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "impo...

17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Ba...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.